[Constraints matrix for the concept of new cancerostatics with activation in optimally superacidulated carcinomatous tissue (author's transl)].

Maintained immunoreaction -- an essential factor for the prospects of healing in any type of cancer therapy -- can be warranted on principle by developing cancerostatics with substantially increased selectivity. One way to approach this goal is the synthesis of functionally masked cancerostatics the active form of which is released only in optimally superacidulated carcinomatous tissue. Used as a key element for such a liberation is a enzyme contained in the cancer cells in its highly concentrated free form. The activity curve of this enzyme must have a pronounced optimum in a span of pH equal 5 to 6. Bonding the active form of, say, an alkylizing molecular group may be glycosidic by nature. Finally, a model is outlined which duly considers the various pharmaco-kinetic aspects.